Form 4: Amgen Director Robert Eckert Reports Acquisition of Common Stock and Dividend Equivalents

Director Robert Eckert reports acquisition of Amgen common stock and dividend equivalents through vested restricted stock units and dividend reinvestment.

Summary

• Robert Eckert, a director at Amgen Inc., filed a Form 4 on May 31, 2024, reporting changes in beneficial ownership of Amgen's common stock.
• The report indicates that Eckert acquired 719 shares of common stock at $0 through the vesting of Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• These RSUs vested immediately and are paid in shares of the company's common stock on a one-to-one basis.
• Eckert also holds 2,881 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan.
• Following the reported transaction, Eckert beneficially owns 23,715 shares of Amgen common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of director stock transactions. The acquisition of shares by a director is generally viewed positively, but this is part of a compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Director share acquisitions are common and are viewed as a sign of confidence in the company's prospects. This is a routine filing related to director compensation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholder confidence due to the director's increased stake in the company.

Key Dates